Total Payments
$2,678
2024 Payments
$131.33
Companies
18
Transactions
130
Medicare Patients
1,696
Medicare Billing
$134,338
Payment Breakdown by Category
Food & Beverage$2,678 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,678 | 130 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $617.35 | 30 | $0 (2024) |
| Amgen Inc. | $604.37 | 39 | $0 (2024) |
| Gilead Sciences, Inc. | $315.70 | 13 | $0 (2019) |
| SANOFI-AVENTIS U.S. LLC | $278.13 | 10 | $0 (2019) |
| Abbott Laboratories | $186.36 | 4 | $0 (2019) |
| BIOTRONIK INC. | $172.19 | 3 | $0 (2017) |
| Aralez Pharmaceuticals US Inc. | $109.72 | 9 | $0 (2017) |
| Philips Electronics North America Corporation | $72.28 | 4 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $67.07 | 4 | $0 (2019) |
| CVRx, Inc. | $52.13 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $131.33 | 7 | CVRx, Inc. ($52.13) |
| 2023 | $67.00 | 4 | Merck Sharp & Dohme LLC ($19.05) |
| 2022 | $84.52 | 4 | Philips Electronics North America Corporation ($42.46) |
| 2021 | $41.67 | 3 | Novartis Pharmaceuticals Corporation ($30.18) |
| 2020 | $58.86 | 4 | Novartis Pharmaceuticals Corporation ($27.00) |
| 2019 | $385.35 | 17 | Novartis Pharmaceuticals Corporation ($129.94) |
| 2018 | $670.72 | 27 | Amgen Inc. ($287.18) |
| 2017 | $1,238 | 64 | SANOFI-AVENTIS U.S. LLC ($260.79) |
All Payment Transactions
130 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/06/2024 | Philips North America LLC | (CK4) MCOT (Device) | Food and Beverage | Cash or cash equivalent | $13.26 | General |
| Category: Medical Device | ||||||
| 09/16/2024 | Philips North America LLC | (CK4) MCOT (Device) | Food and Beverage | Cash or cash equivalent | $17.62 | General |
| Category: Medical Device | ||||||
| 07/15/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $18.99 | General |
| Category: Cardiology | ||||||
| 02/27/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $15.20 | General |
| Category: Cardiovascular | ||||||
| 02/23/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $14.13 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 02/09/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $23.72 | General |
| Category: Heart Failure and Hypertension | ||||||
| 01/12/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $28.41 | General |
| Category: Heart Failure and Hypertension | ||||||
| 11/20/2023 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $19.05 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/18/2023 | Philips Electronics North America Corporation | (5050) Extended Holter (Device) | Food and Beverage | Cash or cash equivalent | $13.37 | General |
| Category: Medical Device | ||||||
| 07/18/2023 | Lexicon Pharmaceuticals, Inc. | Inpefa (Drug) | Food and Beverage | In-kind items and services | $16.97 | General |
| Category: Inhibitor of SGLT2 and SGLT1 | ||||||
| 01/23/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $17.61 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/04/2022 | Philips Electronics North America Corporation | (5044) MCOT (Device) | Food and Beverage | Cash or cash equivalent | $24.88 | General |
| Category: Medical Device | ||||||
| 10/06/2022 | Philips Electronics North America Corporation | (5044) MCOT (Device) | Food and Beverage | Cash or cash equivalent | $17.58 | General |
| Category: Medical Device | ||||||
| 03/03/2022 | Merck Sharp & Dohme LLC | VERQUVO (Drug) | Food and Beverage | In-kind items and services | $21.61 | General |
| Category: CARDIOVASCULAR | ||||||
| 01/27/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.45 | General |
| Category: DIABETES | ||||||
| 08/09/2021 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $11.49 | General |
| Category: Cardiology | ||||||
| 08/03/2021 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $18.71 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/06/2021 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $11.47 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/23/2020 | Philips Electronics North America Corporation | (7999) SRC Undivided (Device) | Food and Beverage | Cash or cash equivalent | $16.45 | General |
| Category: Devices | ||||||
| 08/12/2020 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.41 | General |
| Category: Cardiology | ||||||
| 02/06/2020 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $12.46 | General |
| Category: CARDIOVASCULAR | ||||||
| 01/08/2020 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $14.54 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/21/2019 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $14.52 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/06/2019 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.33 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/17/2019 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $19.71 | General |
| Category: CARDIOVASCULAR | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 408 | 431 | $162,887 | $28,511 |
| 2022 | 11 | 455 | 558 | $280,252 | $39,195 |
| 2021 | 9 | 401 | 468 | $240,661 | $32,314 |
| 2020 | 11 | 432 | 531 | $249,679 | $34,318 |
Total Patients
1,696
Total Services
1,988
Medicare Billing
$134,338
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 137 | 153 | $67,425 | $13,501 | 20.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 26 | 26 | $19,010 | $4,356 | 22.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 64 | 67 | $24,980 | $3,665 | 14.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 17 | 17 | $10,370 | $2,370 | 22.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 32 | 32 | $23,700 | $1,830 | 7.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 17 | 17 | $10,866 | $1,670 | 15.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 69 | 69 | $3,036 | $785.92 | 25.9% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Office | 2023 | 46 | 50 | $3,500 | $333.30 | 9.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 89 | 121 | $61,105 | $9,972 | 16.3% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2022 | 16 | 16 | $60,987 | $7,102 | 11.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 35 | 36 | $24,480 | $4,512 | 18.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 23 | 23 | $22,195 | $3,738 | 16.8% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2022 | 16 | 30 | $9,900 | $3,062 | 30.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2022 | 49 | 49 | $31,850 | $2,679 | 8.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 48 | 50 | $20,000 | $2,587 | 12.9% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2022 | 11 | 44 | $8,580 | $2,135 | 24.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 18 | 18 | $11,700 | $1,146 | 9.8% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2022 | 15 | 15 | $14,625 | $907.09 | 6.2% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Office | 2022 | 102 | 110 | $7,700 | $736.30 | 9.6% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Facility | 2022 | 17 | 17 | $5,100 | $396.99 | 7.8% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 16 | 29 | $2,030 | $222.88 | 11.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 81 | 115 | $57,067 | $9,726 | 17.0% |
| 78452 | Nuclear medicine study of vessels of heart using drugs or exercise multiple studies | Office | 2021 | 13 | 13 | $49,552 | $5,817 | 11.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 57 | 65 | $26,078 | $3,154 | 12.1% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Facility | 2021 | 50 | 50 | $32,500 | $3,143 | 9.7% |
About Dr. Gurkan Taviloglu, M.D
Dr. Gurkan Taviloglu, M.D is a Cardiovascular Disease healthcare provider based in Wauchula, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1811919889.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gurkan Taviloglu, M.D has received a total of $2,678 in payments from pharmaceutical and medical device companies, with $131.33 received in 2024. These payments were reported across 130 transactions from 18 companies. The most common payment nature is "Food and Beverage" ($2,678).
As a Medicare-enrolled provider, Taviloglu has provided services to 1,696 Medicare beneficiaries, totaling 1,988 services with total Medicare billing of $134,338. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Nuclear Cardiology, Cardiovascular Disease
- Location Wauchula, FL
- Active Since 07/25/2006
- Last Updated 08/02/2023
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1811919889
Products in Payments
- ENTRESTO (Drug) $585.61
- Repatha (Biological) $350.42
- PRALUENT (Drug) $278.13
- Corlanor (Drug) $253.95
- Ranexa (Drug) $125.00
- Mitra Clip system (Device) $121.35
- BRILINTA (Drug) $69.36
- YOSPRALA (Drug) $59.42
- Barostim Neo System (Device) $52.13
- ZONTIVITY (Drug) $50.30
- PRALUENT ALIROCUMAB INJECTION (Biological) $45.08
- Circulatory Support (Device) $43.76
- (5044) MCOT (Device) $42.46
- VERQUVO (Drug) $40.66
- LEQVIO (Drug) $31.74
- (CK4) MCOT (Device) $30.88
- CRT-Ds (Device) $21.25
- JARDIANCE (Drug) $20.45
- XARELTO (Drug) $17.47
- Inpefa (Drug) $16.97
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.